Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TD001 |
| Synonyms | |
| Therapy Description |
TD001 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FOLH1 (PSMA) conjugated to exatecan, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 311). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TD001 | TD-001|TD 001 | PSMA Antibody 23 | TD001 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FOLH1 (PSMA) conjugated to exatecan, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 311). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07258407 | Phase Ib/II | TD001 | A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer | Not yet recruiting | USA | 0 |